Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
US-2018265524-A1 · Sep 20, 2018 · US
Compositions and methods for inhibition of cathepsins
US9458103B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9458103-B2 |
| Application number | US-201414505165-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 2, 2014 |
| Priority date | Mar 23, 2012 |
| Publication date | Oct 4, 2016 |
| Grant date | Oct 4, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.
First claim
Opening claim text (preview).
We claim: 1. A compound of formula I: or a solvate or pharmaceutically acceptable salt thereof, wherein X is C(═O); n is 0 or 1; m is 0 or 1; p is 0 or 1; R 1 and R 2 are hydrogen; R 3 and R 5 are independently selected from the group consisting of hydroxyl, fluoro, and chloro; and R 4 is selected from the group consisting of hydroxyl, benzoyl, and halo.…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9458103B2 cover?
- This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.
- Who is the assignee on this patent?
- Oxigene Inc, Univ Baylor, Mateon Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07C337/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).